TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $36.94 and last traded at $35.62, with a volume of 4498231 shares changing hands. The stock had previously closed at $34.42.
Analyst Ratings Changes
Several research firms have recently commented on TGTX. JPMorgan Chase & Co. raised their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday. Finally, StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $40.67.
View Our Latest Stock Analysis on TG Therapeutics
TG Therapeutics Stock Up 9.2 %
The business has a 50-day simple moving average of $30.95 and a 200-day simple moving average of $28.43. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company has a market cap of $5.98 billion, a price-to-earnings ratio of -384.36 and a beta of 2.30.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. On average, equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.
Insider Transactions at TG Therapeutics
In related news, CFO Sean A. Power sold 11,337 shares of the company's stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the transaction, the chief financial officer now directly owns 670,632 shares of the company's stock, valued at $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 10.50% of the company's stock.
Institutional Trading of TG Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TGTX. Arizona State Retirement System boosted its position in shares of TG Therapeutics by 0.9% in the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock valued at $1,283,000 after purchasing an additional 364 shares during the period. Blue Trust Inc. grew its position in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 371 shares during the last quarter. Summit Investment Advisors Inc. increased its stake in TG Therapeutics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after buying an additional 463 shares during the period. Brookstone Capital Management lifted its stake in shares of TG Therapeutics by 3.7% in the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock worth $527,000 after acquiring an additional 624 shares during the period. Finally, Daymark Wealth Partners LLC boosted its holdings in shares of TG Therapeutics by 1.7% in the fourth quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock valued at $1,249,000 after acquiring an additional 689 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.
About TG Therapeutics
(
Get Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
See Also
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
